» Articles » PMID: 24695011

Prevalence and Clinical Characteristics of Adult Polymyositis and Dermatomyositis; Data from a Large and Unselected Norwegian Cohort

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2014 Apr 4
PMID 24695011
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The occurrence of polymyositis (PM) and dermatomyositis (DM) in the general population is largely unknown and unbiased data on clinical and laboratory features in PM/DM are missing. Here, we aim to identify and characterise every PM/DM patient living in southeast Norway (denominator population 2.64 million), 2003-2012.

Method: Due to the structure of the Norwegian health system, all patients with PM/DM are followed at public hospitals. Hence, all public hospital databases in southeast Norway were screened for patients having ICD-10 codes compatible with myositis. Manual chart review was then performed to identify all cases meeting the Peter & Bohan and/or Targoff classification criteria for PM/DM.

Results: The ICD-10 search identified 3160 potential myositis patients, but only 208/3160 patients met the Peter & Bohan criteria and 230 the Targoff criteria (100 PM, 130 DM). With 56 deaths during the observation period, point prevalence of PM/DM was calculated to 8.7/100 000. Estimated annual incidences ranged from 6 to 10 /1 000 000, with peak incidences at 50-59 (DM) and 60-69 years (PM). Myositis specific antibodies (Jo-1, PL-7, PL-12, signal recognition particle (SRP) and Mi-2) were present in 53% (109/204), while 137/163 (87%) had pathological muscle MRI. Frequent clinical features included myalgia (75%), arthritis (41%) dyspnoea (62%) and dysphagia (58%). Positive anti-Jo-1, present in 39% of DM and 22% of PM cases, was associated with dyspnoea, arthritis and mechanic hands.

Conclusions: Our data indicate that the population prevalence of PM/DM in Caucasians is quite low, but underscores the complexity and severity of the disorders.

Citing Articles

Inflammasomes and idiopathic inflammatory myopathies.

Sun R, Chu J, Li P Front Immunol. 2024; 15:1449969.

PMID: 39723212 PMC: 11668653. DOI: 10.3389/fimmu.2024.1449969.


An update on autoantibodies in the idiopathic inflammatory myopathies.

Allameen N, Ramos-Lisbona A, Wedderburn L, Lundberg I, Isenberg D Nat Rev Rheumatol. 2024; 21(1):46-62.

PMID: 39609638 DOI: 10.1038/s41584-024-01188-4.


Case report: Rapid clinical improvement of anti-HMGCR immune-mediated necrotizing myopathy treated with efgartigimod.

Zeng Q, Chen K, Zeng L, Xu L, Tan S Front Immunol. 2024; 15:1495415.

PMID: 39569185 PMC: 11576441. DOI: 10.3389/fimmu.2024.1495415.


Clinical characteristics of idiopathic inflammatory myopathies related to anti-SRP: a single center experience.

Tang Q, Xie X, He J, Li F, Chen J, Mao N Sci Rep. 2024; 14(1):25788.

PMID: 39468198 PMC: 11519947. DOI: 10.1038/s41598-024-74940-1.


Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives.

Kim H, Werth V Ann Dermatol. 2024; 36(5):257-265.

PMID: 39343752 PMC: 11439981. DOI: 10.5021/ad.24.022.